SLC2A1 and breast carcinoma: CD44v6, CAIX, CAXII, and GLUT1 were expressed in 44 cases (33.3%), 9 cases (6.8%), 36 cases (27.1%), and 41 cases (31.3%) of male breast cancers, respectively.